Skip to main content

Gout

RheumNow Podcast square
Dr. Jack Cush reviews and highlights his favorite abstracts and presentations from last week's virtual EULAR 2021 meeting. COSMOS: Guselkumab in TNF-IR PsA. # OP0230m Coates LC, et al. C-OPTIMISE:…
RT @RichardPAConway: Dr Dehlin presents Swedish data showing ⬆️ risk of all cause mortality (HR: 1.08 (95% CL: 1.05-

Richard Conway RichardPAConway

3 months 3 weeks ago
Dr Dehlin presents Swedish data showing ⬆️ risk of all cause mortality (HR: 1.08 (95% CL: 1.05-1.11) and most comorbidities but a ⬇️ risk dementia in gout 0.68 (0.60-0.77) @RheumNow #EULAR2021 Abstr#OP0208 https://t.co/0ojpSbfIHM
RT @Janetbirdope: My toe hurts & it’s a killer! Gout is related to ⬆️comorbidities - clusters incl no comorbid

Janet Pope Janetbirdope

3 months 3 weeks ago
My toe hurts & it’s a killer! Gout is related to ⬆️comorbidities - clusters incl no comorbidities to worse outcomes if CRF in gout. HTN⬆️ Gout has SNIPs assoc w HTN & May be the cause. Incident Gout assoc with Acute coronary syndrome OP0193 OP0192 #EULAR2021 @RheumNow @eular_org https://t.co/CS6o0T1FL2
Novartis announced that Cosentyx (secukinumab) has received FDA approval for treatment of children and adolescents with

Dr. John Cush RheumNow

3 months 3 weeks ago
Novartis announced that Cosentyx (secukinumab) has received FDA approval for treatment of children and adolescents with moderate to severe plaque psoriasis #EULAR2021 https://t.co/JlkmjLwqQ8
EULAR19.abstract.jpg (keep)
Many great presentations this week at EULAR 2021 will feature industry sponsored clinical trials and reports.  Often these become the pivotal studies for regulatory approval and the annual congresses…
×